Immunosuppressive treatment regimens in 95 NPSLE patients with 101 NPSLE events
| Neuropsychiatric events for which immunosuppressive therapy was initiated (n=101) | |
| Treatment regimen | |
| Induction | 24 (24) |
| Induction and maintenance | 74 (73) |
| General | 3 (3) |
| Type of medication | |
| Methylprednisolone | 54 (53) |
| Prednisone | 98 (97) |
| Cyclophosphamide | 43 (42) |
| NIH, 6x | 29 (67) |
| NIH, complete (12x) | 10 (23) |
| Euro-Lupus | 4 (10) |
| Azathioprine | 49 (49) |
| Mycophenolate mofetil | 12 (12) |
| Biological | 3 (3) |
| Rituximab | 2 (2) |
| Belimumab | 1 (1) |
| Other | 4 (4) |
| IVIG | 2 (2) |
| Methotrexate | 1 (1) |
| Ciclosporin | 1 (1) |
| Concomitant treatment* | |
| Hydroxychloroquine | 66 (65) |
| Antiplatelet | 54 (53) |
| Anticoagulant | 18 (18) |
Results are presented as n (%).
*Treatment already present at time of presentation with NP symptoms or started for ischaemic manifestations.
IVIG, intravenous immune globulin; NIH, National Institute of Health; NP, neuropsychiatric; NPSLE, neuropsychiatric SLE.